Healthtech solutions company Brain+ A/S (Nasdaq First North:BRAINP) announced on Tuesday that Ayla – your CST Assistant has received registration with the UK Medicines and Healthcare products Regulatory Agency (MHRA).
This registration follows successful certification as a Class I Medical Device Software under UK Conformity Assessment (UKCA) regulations. With the UKCA marking secured, Ayla – your CST Assistant is poised for commercial launch as the only medical device software in the UK providing Cognitive Stimulation Therapy (CST) for dementia patients.
Ayla will become commercially available on various digital distribution platforms within the next few days, facilitating outreach to NHS sites and positioning Brain+ to sign initial sales contracts in Q4 2024. As a pioneering software solution, Ayla enhances the delivery of group-based CST, which is endorsed in NICE guidelines as the primary non-pharmacological treatment for dementia. It allows for tailored CST delivery and minimizes preparation time by providing curated content developed with leading experts.
Upcoming certifications will ensure compliance with NHS data privacy, cyber security and usability standards, including NHS DSPT and NHS DTAC requirements. A CREST-accredited penetration test will also be conducted, enabling Ayla – your CST Assistant to be included in the G-Cloud 14 procurement platform by the end of October, streamlining access for NHS trusts.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024